Introduction
Avian influenza (AI) is an enormous global threat, both to the poultry industry and human public health, with an economic loss of over US$ 10 billion estimated for H5N1 outbreaks [1] .
Wild waterfowl (Anseriformes) and shorebirds (Charadriformes) worldwide are natural reservoirs of influenza A viruses. Domestic ducks are generally susceptible to AI virus infection, but until the emergence of the H5N1 viruses, in Asia in 2002, ducks generally showed no clinical disease. These recent H5N1 viruses can cause severe disease in ducks with high mortality and both sick and clinically normal ducks infected with these viruses shed high virus loads from the cloaca and the oropharynx [2] . In many of the countries that have experienced the recent H5N1 epizootic, domestic ducks mix closely with terrestrial poultry especially in small village farms, households and live poultry markets. Recurrent outbreaks in these countries have been linked to unapparent infections in domestic ducks.
In countries like Vietnam, China and Indonesia, with large duck populations and persistent H5N1 disease, AI vaccines are increasingly being used as a tool in control programs for highly pathogenic avian influenza (HPAI) viruses in domestic ducks as well as other commercial and backyard poultry [3] . On a flock basis, vaccination can help break the infectious cycle, in combination with vigilant monitoring and strong biosecurity measures [4] . However, domestic ducks can be infected sub-clinically with other circulating AI virus strains. Some of the AI viruses of low or high pathogenicity that are currently circulating in areas that have experienced H5N1 outbreaks include H5N1, H5N2, H6N1, H7N1, H7N2, H7N3 and H9N2 [5] . Vaccination complicates AI sero-surveillance using commonly available diagnostic tests, as for example in China, Vietnam and Indonesia, where duck flocks are being vaccinated with killed H5N1 vaccines, vaccinated and naturally infected birds will both produce H5-specific antibody.
Vaccination to control AI should be part of a science-based control strategy that includes suitable monitoring of all flocks at risk including vaccinated flocks [6] . As part of this approach, various strategies have been developed for differentiating infected from vaccinated animals (DIVA) where AI vaccination is used to enhance virus surveillance, prevent unnecessary culling of birds, and regulate poultry vaccination, movement and trade [7] .
Although several DIVA strategies based on the specificity of antibody responses have been devised, they have serious limitations, especially for testing duck species in countries like China, Vietnam and Indonesia [8] and [9] . Ducks in these countries are currently being vaccinated with reverse genetics-derived killed H5N1 vaccines that are relatively cheap and have shown good potency against field viruses. However, this does not allow the use of the heterologous neuraminidase (NA) type of DIVA strategy. Circulation of other AI viruses in these countries will generate nuclear protein (NP)-specific and non structural (NS)1-specific antibody responses that complicate use of NP-and NS1-specific tests to monitor H5N1 infection. Also any HxN1 viruses (e.g. H6N1, H7N1) circulating will complicate use of N1 antibody testing if a heterologous NA vaccination DIVA strategy is in place. At present the NS1-specific tests have not been fully validated for use in an AI monitoring system and the heterologous NA DIVA approach has only been validated for low pathogenicity AI virus surveillance in chickens and turkeys [7] .
Considering the nature of the domestic duck industry in countries like China, Vietnam and Indonesia, and the difficulty with being able to identify vaccinated ducks, we have considered an alternative strategy that could be used for sero-surveillance in ducks when vaccination is officially used as part of a H5N1 control program. This involves inclusion of an exogenous antigen in the vaccine that can be used as a positive marker for vaccination. Testing for an antibody response to the marker would confirm that the approved vaccine has been used and a concurrent test for H5 antibody would determine if adequate H5 antibody responses were present in the flock to give an indication of vaccine efficacy and the effectiveness of vaccine delivery. If high H5 antibody responses were present relative to the normal vaccine response curve this could indicate recent infection and trigger further virology investigation, enabling a novel DIVA strategy. The positive identification of vaccinated birds would allow the authorities to regulate vaccination especially in small commercial flocks, village and backyard poultry, where record keeping and biosecurity is poor.
We have previously evaluated tetanus toxoid (TT) as an exogenous marker for AI vaccines in chickens and showed that there is no interference with TT or AI H-specific antibody responses in TT-and AI-co-vaccinated chickens [10] . The TT marker was selected on the basis that chickens are highly resistant to tetanus (chicken toxic dose is 350,000 times the equine toxic dose per gram body weight) [11] , are not routinely vaccinated with TT, and naturally existing antibodies to TT are absent in chickens from a variety of sources.
Furthermore, the antigen is of relatively low cost to manufacture, has minimal regulatory and market acceptance issues and development of an accurate and relatively inexpensive antibody test to the antigen is possible [10] . In this study, we evaluate the levels of naturally acquired antibodies to TT in wild and domestic ducks from Australia, the immunogenicity of TT in Muscovy ducks, and interference by TT on H6-or TT-seroconversion in ducks given separate TT and H6N2 AI vaccines or combined TT/H6N2 vaccines. Our data supports the suitability of the TT marker for AI sero-surveillance in ducks. Mackenzie, Curtin University), was propagated according to OIE protocols [12] . Briefly, H6N2 was cultured using 9-to 11-day-old embryonated, specific pathogen-free (SPF) fowl eggs [10] . Harvested allantoic fluid containing H6N2 virus was inactivated with formalin 0.1% (v/v) for 65 h at 37 °C, and virus inactivation confirmed by embryonated fowl egg inoculation. The HA titre of the inactivated H6N2 AI virus stock (2 7 HA units) was determined using the OIE standard protocol [12] as previously described [10] . 
Materials and methods

Birds
Blood collection
Blood samples were collected by venipuncture from wing or leg veins at week 0 (pre-bleed)
and at specified weeks post-vaccination. Blood was collected into glass or serum clot activator-treated plastic vacutainers (Starsedt, Germany) and serum separated after clot retraction was stored at 4 °C prior to use in assays and transferred to −80 °C for long-term storage.
Determination of TT antibody levels by competitive ELISA
Levels of TT-specific antibodies in duck sera were determined by competitive ELISA.
Immunosorbent ELISA plates (Greiner BioOne, Germany) were coated overnight at 4 °C in a 
Haemagglutination Inhibition (HI) assay
H6-specific antibody titres were determined by HI assay using procedures described in the WHO Manual on Animal Influenza Diagnosis and Surveillance [13] . Pre-incubation of the duck serum with receptor destroying enzyme (Denka Seiken Co. Ltd., Japan) was conducted to remove non-specific inhibitors of haemagglutination. The antigen used was the homologous H6N2 virus (A/Coot/Perth/2727/79) at a dilution determined by haemagglutination (HA) test to contain 4 HA units. The HI titre was determined as the highest dilution of serum giving complete inhibition of haemagglutination and the data are expressed as mean antibody titres (log 2 ) + S.E.M.
Statistical analysis
The two-tailed unpaired Student's t test assuming unequal variance between means was used to assess statistical significance between groups (*P < 0.05, **P < 0.01).
Results
Natural seroprevalence to tetanus toxoid (TT) in wild and domestic ducks
The presence of naturally acquired antibodies to TT was determined by competitive ELISA using sera obtained from wild and domestic ducks from various geographical locations ( Antibody levels to TT and H6 antigens were determined by competitive ELISA, and HI assay, respectively. Prior to vaccination, all ducks (n = 30) were negative for TT-and H6-specific antibodies (Fig. 2) . The levels of TT-specific antibodies produced in co-vaccinated ducks were not strongly positive until after the second vaccination ( Fig. 2A ). There was a significantly higher TT-specific antibody response observed in ducks given 0.1 mg TT/AI compared to 0.3 mg TT/AI vaccine at week 6 post-vaccination (P < 0.05). However, there were no significant differences in antibody levels to TT at other timepoints, regardless of the TT vaccine dose.
H6 antibody titres, determined by HI assay, were found to be low in TT and AI co-vaccinated ducks until 2 weeks following second vaccination (Fig. 2B) . However, at week 6 postvaccination, no significant differences were observed between the H6 antibody titres from birds in any of the groups regardless of the TT vaccine dose.
Antibody responses in ducks vaccinated with a combined TT and inactivated H6N2 AI vaccine
Next, a divalent vaccine composed of both TT and whole inactivated H6N2 antigens emulsified with mineral oil (Montanide ISA-70 VG) was prepared, using three separate doses of TT (0.15, 0.3 and 0.6 mg), as described previously [10] . The vaccine was delivered Fig. 3A and B) and H6 by HI test (Fig. 3C and D). Note that the AI vaccine only group remained negative for antibodies against TT throughout the 19-week study ( Fig. 3A and B) . Likewise, the TT vaccine only group remained H6 seronegative for the duration of the experiment (Fig. 3C and D) .
Following a single vaccination, the level of TT antibodies found in ducks given the combined TT/AI vaccine compared with the TT vaccine alone (both 0.3 mg TT) showed no significant differences with peak levels observed at 8 weeks post-vaccination (Fig. 3A) . At 19 weeks post-single vaccination ducks showed declining TT antibody levels. However, after a second vaccination, birds in the TT/AI vaccine dose groups showed peak levels of TT-specific antibodies 4 weeks later (at week 8 post-priming), which then slightly declined by week 19 post-vaccination (Fig. 3B) . With the exception of birds in the 0.15 mg TT/AI group at week 2, which produced significantly higher TT-specific antibody levels than the TT control group (P < 0.01), no significant differences in levels of TT-specific antibodies were found between the TT/AI vaccine groups and the TT only group at any other time point, regardless of TT dose. Notably, the 0.3 mg TT/AI group produced a high level of TT antibodies throughout the experiment, which was significantly higher than the 0.15 mg TT/AI and the 0.6 mg TT/AI vaccine groups at week 8 (P < 0.05). Moreover, twice-vaccinated ducks produced significantly higher TT antibody levels than ducks given a single vaccination at week 6 for the TT only group (P < 0.01) and at weeks 6 and 8 post-vaccination for the 0.3 mg TT/AI group (P < 0.01).
Low titres of H6-specific antibodies, as determined by HI assay, were produced at week 2 post-single vaccination in ducks with no significant differences found between the AI only and the 0.3 mg TT/AI vaccine group (Fig. 3C) . At week 4, a low titre of H6-specific antibodies was observed in the 0.3 mg TT/AI group only. H6-specific antibodies were not detected beyond week 4 in AI-vaccinated birds given a single dose of vaccine. In contrast, markedly higher H6 antibody titres were observed in ducks given a double vaccination with AI and the different doses of TT/AI vaccines compared to ducks given a single vaccination ( Fig. 3D , P < 0.05). However, H6-specific antibody titres significantly decreased by week 19 post-vaccination. At weeks 6 and 8 post-vaccination, no significant differences between H6
HI antibody titres were detected for any of the TT/AI vaccine dose groups compared with the H6N2 vaccine control group.
Duck IgY subclass responses to TT and H6N2 in birds immunised with combined TT and inactivated AI vaccines
We also analysed the abovementioned double-vaccinated ducks from the 0. 
Discussion
Globally, the H5N1 epizootic still continues and the recent increase of outbreaks in existing and newly infected countries is of great concern for public and animal health and has some countries on constant alert [14] . The Food and Agricultural Organisation (FAO), World
Health Organisation (WHO) and World Organisation for Animal Health (OIE) have come together to make recommendations on the control of AI and have stated that in many regions of the world, the control of AI is being jeopardised by inadequate control programs. Control of H5N1 HPAI by stamping out involves detection of infection and systematic culling of infected animals within a certain geographical radius [15] . However, culling of poultry is very costly, resulting in economic losses in the order of millions of dollars and loss of animal protein supply in the diet of poorer farmers and villagers in developing countries. In developing countries, where there is inadequate or no compensation, many farmers will simply not advise authorities of outbreaks within their domestic flocks in order to prevent mass culling of uninfected birds. AI control is being managed increasingly in the poultry industry by use of H5 AI vaccination under government-endorsed programmes [16] and [17] .
Vaccination as a tool for the control of AI in poultry assists in slowing virus spread, as vaccinated birds shed lower levels of virus for a shorter period than unvaccinated birds, and limited gene reassortment occurs between species including ducks, geese, chickens and quails in live markets [18] . However, vaccination complicates surveillance of outbreaks of HPAI H5N1, especially in ducks, by serological means as both vaccinated and virus-infected birds produce specific antibody to H5. To improve monitoring of H5N1 control and effective vaccination, vaccination programs should incorporate post-vaccination surveillance [19] and [20] .
Control of H5N1 AI infection in domestic ducks is considered to be an important component of the overall control of this epizootic with the duck being considered the "Trojan horse"
facilitating silent spread of the H5N1 virus in the environment and live bird markets [21] .
Although post-2002 H5N1 viruses can cause severe disease in ducks with high mortality, some infected ducks remain clinically normal and both sick and clinically normal ducks infected with these viruses shed high virus loads from the cloaca and the oropharynx. H5N1-infected ducks may shed virus for 10-20 days [2] and [21] . Massive populations of ducks exist in countries with persistent H5N1 infection, such as China, Vietnam and Indonesia, where duck farming is closely integrated with rice production and is vital for provision of both food and income. H5N1 influenza virus was shown to be prevalent among ducks raised in "open" houses, free-ranging (grazing) ducks, and backyard ducks in Thailand [22] . A critical factor for HPAI persistence has been shown to be free-grazing ducks in wetlands used for double-crop rice production, which feed year round in rice paddies [23] . Without clinical signs, it is unlikely that the farmer will recognise influenza virus infection in affected ducks and thus constant bird-water, bird-bird and bird-human interactions promote transmission of virus over large geographical areas, greatly increasing human and domestic poultry exposure [24] . Influenza virions shed by ducks into water have been known to stay viable for extended periods of time, allowing greater numbers of birds to come into contact with viruscontaminated waters. Depending on humidity, salinity and pH levels, influenza virions in water have been shown to survive for 32 days at 4 °C [25] . Another issue of concern is that all 16 HA and 9 NA AI subtypes circulate in ducks which are usually sub-clinically infected and the duck can be a host that facilitates reassortment of viral gene segments resulting in the evolution of new H5 variants of unknown consequences. In this study a total of 463 wild and domestic ducks that had not been vaccinated were tested for TT-specific antibodies and none were seropositive. We have also screened 1779 chickens in Australia, Hong Kong and China, and all were seronegative for TT antibodies without prior TT vaccination [10] . These birds were from various geographical locations and habitats, 
